Suppr超能文献

排除肌钙蛋白特征后,临床风险评分对疑似急性冠脉综合征的分类性能。

Classification performance of clinical risk scoring in suspected acute coronary syndrome beyond a rule-out troponin profile.

机构信息

College of Medicine & Public Health, Flinders University, Sturt Road, Bedford Park, SA 5042, Australia.

South Australian Department of Health, 11 Hindmarsh Square, Adelaide, SA 5000, Australia.

出版信息

Eur Heart J Acute Cardiovasc Care. 2021 Dec 6;10(9):1038-1047. doi: 10.1093/ehjacc/zuab040.

Abstract

AIMS

High-sensitivity cardiac troponin strategies can provide risk stratification in patients with suspected acute coronary syndrome (ACS) in the emergency department (ED). This study evaluated whether clinical risk scoring improves the classification performance of a rule-out profile in suspected ACS.

METHODS AND RESULTS

Patients presenting to ED with suspected ACS as part of the RAPID-TnT trial randomized to the intervention arm were included. Results ≥5 ng/L were available for all participants in this analysis. We evaluated the Thrombolysis In Myocardial Infarction (TIMI) risk score, History ECG Age Risk factors Troponin (HEART) score, and Emergency Department Assessment of Chest pain Score (EDACS) in addition to a rule-out profile based on the 0/1-h high-sensitivity cardiac troponin T protocol (<5 ng/L or ≤12 ng/L and a change of <3 ng/L at 1-h) using test performance parameters focusing on low-risk groups to identify the primary endpoint (TIMI ≤ 1, HEART ≤ 3, EDACS < 16). Primary endpoint was a composite of type 1/2 myocardial infarction (MI) at index presentation and all-cause mortality or type 1/2 MI at 30 days. A total of 3378 participants were enrolled between August 2015 and April 2019 of which 108 were ineligible/withdrew consent (intervention arm: n = 1638). Sensitivity, specificity, negative predictive value (NPV), and area under the curve (AUC) of the rule-out profile was 94.4%, 76.8%, 99.6%, and 0.86, respectively with 72.9% identified as 'low-risk'. Adding the clinical risk scores did not improve the sensitivity, NPV, or AUC with significantly lower specificity and 'low-risk' classified participants.

CONCLUSIONS

Addition of clinical risk scores to rule-out profile did not demonstrate improved classification performance for identifying the composite of type 1/2 MI at index presentation and all-cause mortality or type 1/2 MI at 30 days.

CLINICAL TRIALS REGISTRATION

URL: https://www.anzctr.org.au. Reg. No. ACTRN12615001379505.

摘要

目的

高敏肌钙蛋白策略可在急诊科(ED)疑似急性冠状动脉综合征(ACS)患者中进行风险分层。本研究评估了临床风险评分是否能提高排除策略在疑似 ACS 中的分类性能。

方法和结果

本研究纳入了 RAPID-TnT 试验中因疑似 ACS 而就诊于 ED 并被随机分配至干预组的患者。本分析中所有参与者均有结果≥5ng/L。我们评估了溶栓治疗心肌梗死(TIMI)风险评分、心电图年龄危险因素肌钙蛋白(HEART)评分和胸痛评分(EDACS),此外还评估了基于 0/1 小时高敏肌钙蛋白 T 方案(<5ng/L 或≤12ng/L,1 小时时变化<3ng/L)的排除策略,使用以低危组为重点的测试性能参数来确定主要终点(TIMI≤1、HEART≤3、EDACS<16)。主要终点是指数表现时的 1/2 型心肌梗死(MI)和全因死亡率或 30 天的 1/2 型 MI 的复合终点。2015 年 8 月至 2019 年 4 月期间共纳入 3378 名患者,其中 108 名不符合条件/撤回同意(干预组:n=1638)。排除策略的敏感性、特异性、阴性预测值(NPV)和曲线下面积(AUC)分别为 94.4%、76.8%、99.6%和 0.86,其中 72.9%被归类为“低危”。添加临床风险评分并没有提高敏感性、NPV 或 AUC,特异性和被归类为“低危”的参与者明显降低。

结论

将临床风险评分添加到排除策略中,并未显示出对识别指数表现时 1/2 型 MI 和全因死亡率或 30 天的 1/2 型 MI 的复合终点的分类性能有所提高。

临床试验注册

网址:https://www.anzctr.org.au。注册号:ACTRN12615001379505。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验